Zacks: Analysts Expect Definitive Healthcare Corp. (NASDAQ:DH) Will Post Earnings of $0.04 Per Share

Wall Street analysts expect Definitive Healthcare Corp. (NASDAQ:DHGet Rating) to announce earnings per share (EPS) of $0.04 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Definitive Healthcare’s earnings. The lowest EPS estimate is $0.03 and the highest is $0.05. The firm is expected to issue its next quarterly earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Definitive Healthcare will report full-year earnings of $0.24 per share for the current financial year, with EPS estimates ranging from $0.22 to $0.26. For the next financial year, analysts anticipate that the firm will report earnings of $0.40 per share, with EPS estimates ranging from $0.36 to $0.45. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Definitive Healthcare.

Definitive Healthcare (NASDAQ:DHGet Rating) last posted its quarterly earnings results on Wednesday, February 23rd. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.02 by $0.02. The company had revenue of $46.31 million for the quarter, compared to analyst estimates of $44.78 million.

Several analysts recently commented on the stock. Canaccord Genuity Group upgraded shares of Definitive Healthcare from a “hold” rating to a “buy” rating and decreased their price target for the stock from $46.00 to $28.00 in a report on Thursday, February 24th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Definitive Healthcare from $21.00 to $26.00 and gave the stock a “hold” rating in a report on Tuesday, April 5th. Credit Suisse Group reduced their target price on shares of Definitive Healthcare from $30.00 to $24.00 and set a “neutral” rating for the company in a research note on Thursday, February 24th. Canaccord Genuity Group upgraded shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Thursday, February 24th. Finally, Barclays reduced their target price on shares of Definitive Healthcare from $26.00 to $23.00 in a research note on Thursday, February 24th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $37.00.

DH stock opened at $23.65 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.77 and a current ratio of 3.77. The firm has a 50 day simple moving average of $23.41 and a 200 day simple moving average of $27.48. Definitive Healthcare has a 52 week low of $18.15 and a 52 week high of $50.30.

In other news, CFO Richard Douglas Booth acquired 2,374 shares of Definitive Healthcare stock in a transaction dated Thursday, March 3rd. The stock was acquired at an average cost of $21.06 per share, for a total transaction of $49,996.44. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Hedge funds have recently made changes to their positions in the stock. Advisor Group Holdings Inc. bought a new position in Definitive Healthcare during the third quarter worth $26,000. Legal & General Group Plc bought a new stake in Definitive Healthcare in the 4th quarter valued at $29,000. Fifth Third Bancorp increased its holdings in Definitive Healthcare by 78.5% in the 1st quarter. Fifth Third Bancorp now owns 1,185 shares of the company’s stock valued at $29,000 after buying an additional 521 shares during the period. Hardy Reed LLC bought a new stake in Definitive Healthcare in the 1st quarter valued at $76,000. Finally, Steph & Co. bought a new stake in Definitive Healthcare in the 4th quarter valued at $88,000. 97.34% of the stock is currently owned by institutional investors and hedge funds.

About Definitive Healthcare (Get Rating)

Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution.

Featured Articles

Get a free copy of the Zacks research report on Definitive Healthcare (DH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Definitive Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definitive Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.